{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 11 October 2005\line \line {\b Roche Diagnostics to 
co-develop IT-enabled prototype psychiatric pharmacogenomics tool} \line \line Tool 
will use information from Roche AmpliChip CYP450 Test\line \line Roche announced 
that Roche and Mayo Clinic, Rochester, Minnesota, USA, have entered into an agreement to investigate 
offering drug selection and dosing information for the treatment of psychiatric patients. Their first 
step is to co-develop a prototype IT- enabled system that will refine and harness Mayo Clinic\u8217?s extensive 
psychiatric and pharmacogenomic clinical expertise. The prototype system will offer drug selection and 
dosing information for a broad range of psychotropic therapeutics based on patient test results from 
Roche\u8217?s AmpliChip CYP450 Test.\line \line \u8220?This is an important step to aid in patient 
care in a specific therapeutic area, especially because psychiatric care often requires the need to 
fine-tune therapy,\u8221? said Heino von Prondzynski, CEO Division Roche Diagnostics and Member of Roche\u8217?s 
Corporate Executive Committee. \u8220?Providing healthcare professionals with the information obtained by 
the AmpliChip CYP450 Test within this context may enable them to select the right medicine and the right 
dose for the individual patient.\u8221?\line \line Psychiatric consultants at the Mayo 
Clinic have been able to genotype their patients for the 2D6 gene and the 2C19 gene for about two years. 
During that time, they have learned that patients appreciate their ability to minimize the side effects 
of the psychotropic medications that are prescribed. The combination of the AmpliChip CYP450 test and 
this new IT-tool, when available, will extend to psychiatrists across the country. This may allow practicing 
psychiatrists to better select and dose their patients\u8217? drugs.\line \line In January 
2005, Roche Diagnostics announced that its first microarray-based test, the AmpliChip CYP450 Test, had 
been cleared by the US Food and Drug Administration (FDA) for diagnostic use in the United States. That 
followed the announcement of September 2004, that the AmpliChip CYP450 Test has the CE mark (\u8220?Conformit\u233? 
Europ\u233?ene\u8221?), allowing the test to be used for diagnostic purposes in the European Union. The test, which 
is powered by Affymetrix microarray technology, analyses a patients Cytochrome P450 2D6 and 2C19 genotypes 
from genomic DNA extracted from a blood sample. Test results allow physicians to consider unique genetic 
information from patients in selecting medications and doses of medications for a wide variety of common 
conditions such as cardiac diseases, pain, and cancer.\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of 
innovative products and services for the early detection, prevention, diagnosis, and treatment of disease, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and 
a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss 
francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 
65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, 
including majority ownership interests in Genentech and Chugai. Additional information about the Roche 
Group is available on the Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law\par}.\line \line \line {\b Additional 
information} \line - AmpliChip CYP450 Press Kit (http://www.roche.com/products.htm)\line - AmpliChip 
Trailer\line - Roche Diagnostics (http://www.roche.com/div_diag.htm)\line - Mayo 
Clinic, Rochester (http://www.mayoclinic.org/rochester)
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}